Nanjing Iaso Biotechnology Co., Ltd.
Clinical trials sponsored by Nanjing Iaso Biotechnology Co., Ltd., explained in plain language.
-
New hope for tough lupus cases: experimental therapy UB-VV410 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (SLE) or lupus kidney disease that hasn't improved with standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs th…
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
New hope for Tough-to-Treat lymphoma: experimental combo trial opens
Disease control Recruiting nowThis early-stage study tests an experimental drug (UB-VV400) alone and with rapamycin in adults with aggressive B-cell lymphoma that has returned or not responded to treatment. About 70 participants will receive the therapy to find the safest dose and check for side effects. The …
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC